Danaher (NYSE:DHR) PT Raised to $278.00

Danaher (NYSE:DHR) had its price objective upped by research analysts at Evercore ISI from $275.00 to $278.00 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has an “outperform” rating on the conglomerate’s stock. Evercore ISI’s price objective would indicate a potential upside of 1.48% from the stock’s previous close.

A number of other analysts have also recently issued reports on the stock. The Goldman Sachs Group lifted their target price on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Stifel Nicolaus upped their price objective on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Barclays raised their target price on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. Leerink Partners upped their price target on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Finally, TD Cowen raised their price objective on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Stock Down 0.2 %

DHR stock opened at $273.95 on Tuesday. The company has a 50 day moving average of $271.14 and a two-hundred day moving average of $258.35. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. Danaher has a 12-month low of $182.09 and a 12-month high of $281.70. The company has a market cap of $202.91 billion, a price-to-earnings ratio of 46.43, a PEG ratio of 4.55 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 earnings per share. On average, equities analysts anticipate that Danaher will post 7.59 earnings per share for the current fiscal year.

Insider Transactions at Danaher

In related news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is currently owned by company insiders.

Institutional Trading of Danaher

Several institutional investors have recently made changes to their positions in DHR. Jones Financial Companies Lllp lifted its position in shares of Danaher by 144.0% during the 4th quarter. Jones Financial Companies Lllp now owns 2,086 shares of the conglomerate’s stock worth $483,000 after buying an additional 1,231 shares during the period. CWA Asset Management Group LLC grew its holdings in shares of Danaher by 14.2% in the 4th quarter. CWA Asset Management Group LLC now owns 3,235 shares of the conglomerate’s stock worth $748,000 after purchasing an additional 402 shares during the last quarter. Belpointe Asset Management LLC increased its position in shares of Danaher by 26.1% during the 4th quarter. Belpointe Asset Management LLC now owns 5,046 shares of the conglomerate’s stock worth $1,168,000 after purchasing an additional 1,044 shares in the last quarter. Lake Street Advisors Group LLC bought a new position in Danaher during the 4th quarter valued at about $957,000. Finally, Capital International Investors boosted its position in Danaher by 9.1% in the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after buying an additional 1,334,781 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.